Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non-muscle-invasive bladder cancer

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 1572-1577

  Lin, Ying Li ^a   Xie, Pei Gen ^b   Ma, Jian Guo ^c  

^a XUZHOU CANCER HOSPITAL   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Biological markers; Cadherins; DNA methylation; Urinary bladder neoplasms

Indexed keywords

AGAROSE; BIOLOGICAL MARKER; BISULFITE; ETHIDIUM BROMIDE; LIQUID NITROGEN; MITOMYCIN; PRIMER DNA; CADHERIN; H-CADHERIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER EPITHELIUM; BLADDER STONE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CDH13 GENE; CELL ADHESION; CHI SQUARE TEST; CONTROLLED STUDY; DISEASE COURSE; DNA DENATURATION; DNA EXTRACTION; DNA METHYLATION; FEMALE; FISHER EXACT TEST; GENE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; TRANSCRIPTION ELONGATION; TUMOR GROWTH; TUMOR INVASION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; BLADDER TUMOR; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCLE; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TIME;

AGED; CADHERINS; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCLES; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84907194318     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892130     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. Cancer J Clin, 2013; 63(1): 11–30
2. Isa F, Xie LP, Hu Z et al: Dietary consumption and diet diversity and risk of developing bladder cancer: results from the South and East China casecontrol study. Cancer Causes Control, 2013; 24(5): 885–95
3. Kaufman DS, Shipley WU, Feldman AS: Bladder cancer. Lancet, 2009; 374(9685): 239–49
4. Jacobs BL, Lee CT, Montie JE: Bladder cancer in 2010: how far have we come? Cancer J Clin, 2010; 60(4): 244–72
5. Kawamoto K, Enokida H, Gotanda T et al: p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun, 2006; 339(3): 790–96
6. Zhang H, Qi F, Cao Y et al: Down-regulated microRNA-101 in bladder transitional cell carcinoma is associated with poor prognosis. Med Sci Monit, 2014; 20: 812–17
7. Li J, Zhang J, Liu Y et al: Increased expression of DNA repair gene XPF enhances resistance to hydroxycamptothecin in bladder cancer. Med Sci Monit, 2012; 18(4): BR156–62
8. Yegin Z, Gunes S, Buyukalpelli R: Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients. DNA Cell Biol, 2013; 32(7): 386–92
9. Kandimalla R, van Tilborg AA, Zwarthoff EC: DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol, 2013; 10(6): 327–35
10. Wang L, Xie PG, Lin YL et al: Aberrant Methylation of PCDH10 Predicts Worse Biochemical Recurrence-Free Survival in Patients with Prostate Cancer After Radical Prostatectomy. Med Sci Monit, 2014; 20: 1363–68
11. Lin YL, Xie PG, Wang L et al: Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy. Med Sci Monit, 2014; 20: 1376–82
12. Andreeva AV, Kutuzov MA: Cadherin 13 in cancer. Genes Chromosomes Cancer, 2010; 49(9): 775–90
13. Lin YL, He ZK, Li ZG et al: Downregulation of CDH13 expression promotes invasiveness of bladder transitional cell carcinoma. Urol Int, 2013; 90(2): 225–32
14. Lin YL, Sun G, Liu XQ et al: Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. J Int Med Res, 2011; 39(1): 179–86
15. Lin YL, Liu XQ, Li WP et al: Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma. Int Urol Nephrol, 2012; 44(1): 111–17
16. Lin Y, Sun G, Liu X et al: Clinical significance of T-cadherin tissue expression in patients with bladder transitional cell carcinoma. Urol Int, 2011; 86(3): 340–45
17. Greene FL: The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg, 2002; 87(7): 13–15
18. Oosterlinck W, Lobel B, Jakse G et al: Guidelines on bladder cancer. Eur Urol, 2002; 41(2): 105–12
19. th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010; 17(6): 1471–74
20. Babjuk M, Oosterlinck W, Sylvester R et al: EAU guidelines on non-muscleinvasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol, 2011; 59(6): 997–1008
21. Jeong P, Min BD, Ha YS et al: RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: potential role in the prediction of tumor progression. Eur J Surg Oncol, 2012; 38(11): 1095–100
22. Kim YJ, Yoon HY, Kim JS et al: HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: arraybased DNA methylation and expression profiling. Int J Cancer, 2013; 133(5): 1135–42
23. Kim WT, Yun SJ, Park C et al: Identification of C16or f74 as a marker of progression in primary non-muscle invasive bladder cancer. LoS One, 2010; 5(12): e15260
24. Li H, Wang J, Xiao W et al: Epigenetic inactivation of KLF4 is associated with urothelial cancer progression and early recurrence. J Urol, 2014; 191(2): 493–501
25. Tada Y, Wada M, Taguchi K et al: The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res, 2002; 62(14): 4048–53
26. Herman JG, Graff JR, Myöhänen S et al: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA, 1996; 93(18): 9821–26
27. Kinoshita K, Minagawa M, Takatani T et al: Establishment of diagnosis by bisulfite-treated methylation-specific PCR method and analysis of clinical characteristics of pseudohypoparathyroidism type 1b. Endocr J, 2011; 58(10): 879–87
28. Guo G, Xu Y, Gong M et al: USP28 is a potential prognostic marker for bladder cancer. Tumour Biol, 2014; 35(5): 4017–22
29. Sánchez-Carbayo M: Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol, 2012; 33(2): 347–61
30. Kim JS, Han J, Shim YM et al: Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer, 2005; 104(9): 1825–33